Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Cobimetinib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Cobimetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Cofetuzumab Pelidotin |
ADC | Solid Tumour | ||
|
Molecule
Cofetuzumab Pelidotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Copanlisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Copanlisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Copper-64 DOTATATE (Diagnostic) |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Copper-64 DOTATATE (Diagnostic)
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Cosibelimab |
Anti-PD-L1 Monoclonal Antibody | Solid Tumour | ||
|
Molecule
Cosibelimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 Monoclonal Antibody |
||||
CPI-1205 (EZH2 Inhibitor) |
EZH2 Inhibitor | Hematologic | ||
|
Molecule
CPI-1205 (EZH2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
||||
Crenolanib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Crenolanib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Crizotinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Crizotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Dacomitinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Dacomitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Dalpiciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Dalpiciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Daratumumab + Hyaluronidase (SC) |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Daratumumab + Hyaluronidase (SC)
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Defactinib |
Focal Adhesion Kinase (FAK) Inhibitor | Solid Tumour | ||
|
Molecule
Defactinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Focal Adhesion Kinase (FAK) Inhibitor |
||||
CobimetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
Cofetuzumab PelidotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
CopanlisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
Copper-64 DOTATATE (Diagnostic)Radiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
CosibelimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 Monoclonal Antibody |
|
CPI-1205 (EZH2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
|
CrenolanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
CrizotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
DacomitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
DalpiciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
Daratumumab + Hyaluronidase (SC)Immunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
DefactinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Focal Adhesion Kinase (FAK) Inhibitor |
|